Navigation Links
Keryx Biopharmaceuticals to Present at 13th Annual BIO CEO and Investor Conference
Date:2/9/2011

NEW YORK, Feb 9, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the 13th Annual BIO CEO & Investor Conference, being held at the Waldorf=Astoria Hotel in New York City.  Mr. Bentsur's presentation will take place on Monday, February 14th, at 3:00 p.m. Eastern Time.

A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 studies is being conducted under a Special Protocol Assessment (SPA) agreement with the FDA. Keryx is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being conducted pursuant to an SPA agreement with the FDA. Keryx is headquartered in New York City.KERYX CONTACT:Lauren FischerDirector, Investor RelationsKeryx Biopharmaceuticals, Inc.Tel: 212.531.5962
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
3. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
4. Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
6. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
7. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
8. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
10. Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
11. Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2019)... Pa. (PRWEB) , ... September 09, 2019 , ... ... Response Technology (IRT) for clinical trial randomization and drug supply chain management, today ... provider for the global life sciences industry. , “The integration between Veeva Vault ...
(Date:9/9/2019)... ... ... Visikol CEO Dr. Michael Johnson recently gave a talk at the ... cell culture models. The inherent problem of characterizing 3D cell culture models is similar ... and therefore traditional wide-field or even confocal microscopy only tells you what is going ...
(Date:9/4/2019)... ... September 03, 2019 , ... ... delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and ... Technology will present at the upcoming Nordic Life Science Days (NLS Days) ...
(Date:8/29/2019)... NEW CENTURY, Kan. (PRWEB) , ... August 28, ... ... baking innovation expertise and wide-ranging DuPont™ Danisco® ingredient solutions to attendees at the ... cutting-edge science to solve today’s baking challenges from optimizing production efficiency to cost ...
Breaking Biology Technology:
(Date:8/27/2019)... ... August 27, 2019 , ... Ambry Genetics ... genetic testing guidelines. In the largest cohort study of its kind, Ambry presents ... patients. , Clinicians use guidelines to inform decisions about which patients should ...
(Date:8/21/2019)... ... 21, 2019 , ... AbSci, a revolutionary synthetic biology company ... of complex protein therapeutics, today announced the appointment of Fred Larimore, PhD, to ... Larimore brings more than 30 years of experience in biopharmaceutical manufacturing and process ...
(Date:8/15/2019)... ... August 15, 2019 , ... Serialization deadlines ... mandates become increasingly complex, and aggregation becomes fully applied in the United States ... best long-term solution. , Until now, most regulations?including the Drug Supply Chain Security ...
Breaking Biology News(10 mins):